Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma

被引:77
|
作者
Vesselle, Guillaume [1 ]
Quirier-Leleu, Camille [2 ]
Velasco, Stephane [1 ]
Charier, Florian [2 ]
Silvain, Christine [2 ]
Boucebci, Samy [1 ]
Ingrand, Pierre [3 ]
Tasu, Jean-Pierre [1 ]
机构
[1] Univ Poitiers Hosp, Diagnost Funct & Therapeut Imaging Dept, 2 Rue Miletrie, F-86021 Poitiers, France
[2] Univ Poitiers Hosp, Dept Gastroenterol, 2 Rue Miletrie, F-86021 Poitiers, France
[3] Univ Poitiers Hosp, Epidemiol & Biostat, Clin Invest Ctr, INSERM CIC P 802, 2 Rue Miletrie, F-86021 Poitiers, France
关键词
Hepatocellular carcinoma (HCC); DEB; -; TACE; Chemoembolization; Predictive factors; Treatment response; CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION; LIVER-CANCER; SURVIVAL; MRECIST; EASL; EMBOLIZATION; ARTERIES; NECROSIS; CRITERIA; RECIST;
D O I
10.1007/s00330-015-3982-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To identify clinical and imaging features associated with complete response (CR) to first session of transarterial chemoembolization (TACE) with drug-eluting beads (DEB) in patients with hepatocellular carcinoma. In this prospective historical cohort, 172 patients with 315 tumours who received at least one DEB-TACE from 2007 to 2013 were studied. Imaging response was evaluated according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST). Age, gender, aetiology of cirrhosis, Child and BCLC scores, particles size, location in the liver, size of the tumour, presence of a capsule, hypervascularisation on DSA and CT/MRI scans, and blush extinction were analysed. After one session of treatment, CR was observed in 36 % of the 315 tumours treated. Nodule size, location in the liver, and complete blush extinction on DSA was statistically correlated to complete response, whereas capsule aspect on imaging and demographic criteria were not. In multivariate analysis only, location in the liver and nodule size were significant features. Tumour location in the segments 1 and 4 is a pejorative factor for CR, whereas tumour size < 5 cm is a positive predictive factor. These criteria could, therefore, be taken into consideration to improve the selection of patients for DEB-TACE. aEuro cent Literature on predictive factors of complete response after DEB-TACE is under-studied. aEuro cent Tumour size < 5 cm is associated with complete response. aEuro cent Location in segments 1 or 4 is a pejorative factor for response. aEuro cent No demographic parameter influences complete response.
引用
收藏
页码:1640 / 1648
页数:9
相关论文
共 50 条
  • [21] Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis
    Yu Liu
    Bo Zhou
    Wentao Tang
    Donghao Xu
    Zhiping Yan
    Li Ren
    Dexiang Zhu
    Guodong He
    Ye Wei
    Wenju Chang
    Jianmin Xu
    European Radiology, 2023, 33 : 1022 - 1030
  • [22] Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis
    Liu, Yu
    Zhou, Bo
    Tang, Wentao
    Xu, Donghao
    Yan, Zhiping
    Ren, Li
    Zhu, Dexiang
    He, Guodong
    Wei, Ye
    Chang, Wenju
    Xu, Jianmin
    EUROPEAN RADIOLOGY, 2023, 33 (02) : 1022 - 1030
  • [23] The Efficiency of Transarterial Chemoembolization with Drug-Eluting Beads in Hepatocellular Carcinoma
    Kucukkapan, Ahmet
    Karakose, Serdar
    EUROPEAN JOURNAL OF GENERAL MEDICINE, 2015, 12 (01): : 44 - 52
  • [24] A case of drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
    Guan, Qingbo
    Song, Lei
    Wang, Kuiyang
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 (04) : 1172 - 1174
  • [25] Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
    Wiggermann, Philipp
    Sieron, Dominik
    Brosche, Christiane
    Brauer, Thomas
    Scheer, Fabian
    Platzek, Ivan
    Wawrzynek, Wojciech
    Stroszczynski, Christian
    MEDICAL SCIENCE MONITOR, 2011, 17 (04): : CR189 - CR195
  • [26] Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features
    Tipaldi, Marcello Andrea
    Ronconi, Edoardo
    Lucertini, Elena
    Krokidis, Miltiadis
    Zerunian, Marta
    Polidori, Tiziano
    Begini, Paola
    Marignani, Massimo
    Mazzuca, Federica
    Caruso, Damiano
    Rossi, Michele
    Laghi, Andrea
    DIAGNOSTICS, 2021, 11 (06)
  • [27] Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST
    Domaratius, Claudia
    Settmacher, Utz
    Malessa, Christina
    Teichgraeber, Ulf
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2021, 27 (01) : 85 - 93
  • [28] Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE)
    Felix Peisen
    Michael Maurer
    Ulrich Grosse
    Konstantin Nikolaou
    Roland Syha
    Dominik Ketelsen
    Christoph Artzner
    Michael Bitzer
    Marius Horger
    Gerd Grözinger
    European Radiology, 2020, 30 : 3782 - 3792
  • [29] Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE)
    Peisen, Felix
    Maurer, Michael
    Grosse, Ulrich
    Nikolaou, Konstantin
    Syha, Roland
    Ketelsen, Dominik
    Artzner, Christoph
    Bitzer, Michael
    Horger, Marius
    Groezinger, Gerd
    EUROPEAN RADIOLOGY, 2020, 30 (07) : 3782 - 3792
  • [30] Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors
    Zhang, Hao
    Wu, Chunxue
    Chen, Miaoling
    Sun, Yuandong
    Han, Jianjun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (06) : 1525 - 1532